The EGFR L858R mutation is known to be oncogenic. The EGFR tyrosine kinase inhibitors osimertinib, dacomitinib, afatinib, erlotinib and gefitinib are FDA-approved for the treatment of patients with EGFR L858R mutant non-small cell lung cancer. 以上药物是FDA批准的用于有EGFR L858R突变的非小细胞肺癌治疗。 穿刺活检做基因测序敏感度更高,检测的panel 所covered gene应该更多。抽血做liquid biopsy测出来的突变丰度不太准。
The EGFR L858R mutation is known to be oncogenic.
The EGFR tyrosine kinase inhibitors osimertinib, dacomitinib, afatinib, erlotinib and gefitinib are FDA-approved for the treatment of patients with EGFR L858R mutant non-small cell lung cancer. 以上药物是FDA批准的用于有EGFR L858R突变的非小细胞肺癌治疗。 穿刺活检做基因测序敏感度更高,检测的panel 所covered gene应该更多。抽血做liquid biopsy测出来的突变丰度不太准。